

Date $-\frac{13}{02}/2024$

Ref. - BDH/SEC/149/2023-24

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001

Subject – Outcome of Board Meeting

Ref. - Compliance pursuant to Regulations 30, 33 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Dear Sirs,

We hereby inform that the Board of Directors of the Company at their meeting held on 13th February 2024, considered and approved the following:-

- Pursuant to Regulation 30(2) read with Schedule III Part A Para A (4) (h) and Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, approved the enclosed herewith the standalone unaudited financial results of the Company for the third quarter and nine months ended 31st December 2023 of the Financial year 2023-24.
- Pursuant to Regulation 33(3) (c) (ii) and Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 enclosed herewith is the Limited Review Report dated 13th February 2024 of M/s. CLB & Associates, Chartered Accountants, Statutory Auditors in respect of standalone unaudited financial results of the Company for the third quarter and nine months ended 31st December 2023 of the Financial year 2023-24.
- Pursuant to Regulation 47(1) (b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the standalone unaudited financial results of the Company for the third quarter and nine months ended 31st December 2023 of the Financial year 2023-24 shall be published in the newspapers as per the format prescribed in Annexure XI pursuant to Sl. No. 3(h) of SEBI Circular bearing no. CIR/CFD/CMD/15/2015.
- Pursuant to Regulation 30(2) read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, approved and recommended appointment of:-Mr. Prabhakar Dalal (DIN: 00544948) as an Independent Director of the Company for term of five consecutive years with effect from 1st April 2024 to 31st March 2029 subject to approval of shareholders.

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 is as follows:

Name of Director – Mr. Prabhakar Dalal (DIN: 00544948)					
Reason for change	Appointment of Mr. Prabhakar Dalal (DIN: 00544948) as Independent Director of the				
_	Company.				
Date of appointment /	The term as a Non – Executive Independent Director of the Company of Mr. Prabhakar				
cessation & Term of	Dalal will commence w.e.f. 1st April 2024 to 31st March 2029 i.e. for a term of five				
appointment	consecutive years, subject to approval of the shareholders.				
1					







CIN: L24100MH1990PLC059299



Brief Profile	Mr. Prabhakar Dalal, aged 70 years holds qualification of M. Com and LL.B. He is a certified associate in banking (CAIIB). He also holds a post graduate diploma in Foreign Exchange and Risk Management (PGDFERM) and Securities Law (PGDSL) and is also a fellow member of the Indian Institute of Banking and Finance (FIIBF).Mr. Prabhakar Dalal is a highly experienced banker in commercial and development banking with 37 years of experience and extensive international exposure across the globe. He has also led Exim Bank's consulting teams to SAARC Development Fund (reactivation of their investment and infrastructure windows) and to Nigerian Exim Bank (launch of their film financing program). He has served as Independent Director on the Boards of several Companies in sector like Finance, Pharmaceuticals, Textiles and Engineering including on the Board of a Lome-headquartered regional development bank viz. West African Development Bank.Mr. Prabhakar Dalal has served as Exim Bank's Resident Representative for Africa based out of Abidjan (Cote d'Ivoire) and Johannesburg (South Africa).
Disclosure of relationship	Mr. Prabhakar Dalal is not related to any Director or Key Managerial Personnel of the
between directors	Company.
Information as required under BSE circular No. LIST/COM/14/2018-19	Mr. Prabhakar Dalal is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Pursuant to Regulation 30(2) read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, approved and recommended appointment of :-Dr. Mitul Patel (DIN: 10413137) as an Independent Director of the Company for term of five consecutive years with effect from 1st April 2024 to 31st March 2029 subject to approval of shareholders.

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 is as follows

Name of Director – Dr. Mitul Patel (DIN: 10413137)						
Reason for change	Appointment of Dr. Mitul Patel (DIN: 10413137) as Independent Director of the					
	Company.					
Date of appointment / cessation& Term of appointment	The term as a Non – Executive Independent Director of the Company of Dr. Mitul Patel will commence w.e.f. 1 st April 2024 to 31 st March 2029 i.e. for a term of five consecutive years, subject to approval of the shareholders.					
Brief Profile	Dr. Mitul Patel, aged 45 years holds the qualification of MBBS and M. D PAED. He has 15 years of clinical experience specializing in child care, case management and communication. He is practicing in consulting child and new born specialist. He has developed individualized treatment plans for a variety of medical conditions and diseases. He analyzes lab tests and blood work to identify abnormalities and prescribe medication to treat chronic and non- life threatening illness.					
Disclosure of relationship between directors	Dr. Mitul Patel is not related to any Director or Key Managerial Personnel of the Company.					
Information as required under BSE circular No. LIST/COM/14/2018-19	Dr. Mitul Patel is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.					









Pursuant to Regulation 30(2) read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, approved andrecommended appointment of :-

Mr. Suresh Chandra Kookada (DIN: 01738594) as an Independent Director of the Company for term of five consecutive years with effect from 1st April 2024 to 31st March 2029 subject to approval of shareholders.

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 is as follows:

Name of Director – Mr. Suresh Chandra Kookada (DIN: 01738594)							
Reason for change	Appointment of Mr. Suresh Chandra Kookada (DIN: 01738594) as Independent						
	Director of the Company.						
Date of appointment /	The term as a Non – Executive Independent Director of the Company of Mr. Suresh						
cessation& Term of	Chandra Kookada will commence w.e.f. 1st April 2024 to 31st March 2029 i.e. f						
appointment	term of five consecutive years, subject to approval of the shareholders.						
Brief Profile	Mr. Suresh Chandra Kookada, aged 64 years is a Practicing Chartered Accountant. He						
Brieffforme	holds qualification of Bachelor's of Commerce and is a member of ICAI and ICSI. He						
	is the proprietor of firm named M/s Suresh Kookada & Co., Chartered Accountants. He						
	has an experience of over 40 years in audits, taxation and corporate matters.						
Disclosure of relationship	Mr. Suresh Chandra Kookada is not related to any Director or Key Managerial						
between directors	Personnel of the Company.						
Information as required	Mr. Suresh Chandra Kookada is not debarred from holding the office of director by						
under BSE circular No.	virtue of any SEBI order or any other such authority.						
LIST/COM/14/2018-19							

The Board Meeting commenced at 4.00 p.m. and concluded at 7.00 p.m.

For BDH Industries Limited,

Nikita Phatak, Company Secretary

Encl. – As above







BDH INDUSTRIES LIMITED

Regd. Off.: Nair Baug, Akurli Road, Kandivli - East, Mumbai - 400101; CIN: L24100MH1990PLC059299

Tel. No. - 022 - 6155 1234; E-mail: investors@bdhind.com; Website: www.bdhind.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

(₹ in Lakhs)

	,	C	Quarter Ended		Nine Months Ended		Year Ended
Sr. No.	Particulars	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	2105.89	1934.91	1219.36	5872.28	5173.63	7445.71
11	Other Income	36.75	40.91	12.70	114.87	50.57	84.10
111	Total Income (I+II)	2142.64	1975.82	1232.06	5987.15	5224.20	7529.81
IV	Expenses						
	(a) Cost of Materials consumed	1595.17	1217.33	791.29	4149.47	3372.26	4779.72
	(b) Changes in inventories of						
	finished goods and work-in-progress	(164.34)	45.54	(146.65)	(135.85)	(70.24)	188.58
	(c) Employee benefits expense	191.24	185.15		552.08	521.25	695.79
	(d) Finance Costs	1.72	2.61	4.19	7.94	8.41	15.79
	(e) Depreciation Expenses	13.48	13.25	14.57	39.84	43.67	56.85
	(f) Other Expenses	134.53	170.06	143.01	445.04	507.84	686.31
	Total expenses	1771.80	1633.94	986.21	5058.52	4383.19	6423.04
V	Profit before tax (V+VI)	370.84	341.88	245.85	928.63	841.01	1106.77
VI	Tax expense						
	Current Tax	93.34	86.04	61.88	233.72	214.19	286.98
	Deferred Tax	0.00	4.62	0.00	4.62	(2.52)	(0.69)
VII	Profit after tax (V-VI)	277.50	251.22	183.97	690.29	629.34	820.48
VIII	Other Comprehensive Income						
	(i) Items that will not be reclassified						
	subsequently to profit or loss	0.00	0.00	0.00	0.00	0.00	(1.47)
	(ii) Income Tax relating to items						
	that will not be reclassified						
	subsequently to profit or loss	0.00	0.00	0.00	0.00	0.00	0.37
	Other Comprehensive Income for the period	0.00	0.00		0.00	0.00	(1.10)
IX	Total Comprehensive Income (VII+VIII)	277.50	251.22	1	690.29	629.34	819.38
X	Paid-up equity share capital	575.73	575.73	1	i	575.73	575.73
	(Face value of ₹ 10/- each)						
ΧI	Other Equity	_	_	_	_	_	4761.63
-	(Excluding Revaluation Reserves)						
XII	Earnings Per Share (Face value of ₹ 10/- each)	4.82	4.36	3.20	11.99	10.93	14.25
	(not annualised except for year ended)			*			
	- Basic and Diluted (₹)				5		-1

Notes:

- The above Standalone Unaudited Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 13th February, 2024. The Statutory Auditors of the Company have carried out limited review of the above Standalone Unaudited Financial Results.
- 2 The entire operations of the Company relate to only one segment viz. 'Pharmaceuticals'.

3 Previous period figures have been regrouped / rearranged wherever necessary to correspond with the figures of current period.

Place: Mumbai

Date: 13th February, 2024

By order of the Board
For BDH Industries Limited

Jayashree Nair

Chairperson & Managing Director

DIN: 00027467





CLB & ASSOCIATES

CHARTERED ACCOUNTANTS

77, Mulji Jetha Bldg., 3rd Floor, 185/ 187, Princess Street, Marine Lines, Mumbai - 400 002. • Tel.: +91-22-22052224, 22066860 E-mail:info@clb.co.in / clb.fca@gmail.com • Website: www.clb.co.in

Independent Auditor's Limited Review Report on (unaudited) standalone financial results for the quarter ended 31st Dec 2023 and year to date results for the period from 1st April 2023 to 31st December 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

The Board of Directors, BDH Industries Ltd. Mumbai

We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of BDH Industries Limited ("the Company") for the quarter ended 31st December 2023 and year to date results for the period from 1st April to 31st December 2023 ("the statement").

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting "("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.

This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement , prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CLB & Associates Chartered Accountants

S. Sarupria

Partner

FRN 124305W

M. No. 035783 Place: Mumbai

Date: 13th February 2024 UDIN: 24035783BKENSC7622

ACCO